79
Participants
Start Date
November 30, 2014
Primary Completion Date
February 28, 2019
Study Completion Date
June 30, 2019
FPA144
FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
National Taiwan University Hospital, Taipei
National Cheng Kung University Hospital, Tainan City
Weill Cornell Medical Center, New York
Taipei Veterans General Hospital, Taipei
University of Pennsylvania, Philadelphia
Sarah Cannon Research Institute, LLC, Nashville
Vanderbilt University Medical Center, Nashville
China Medical University Hospital, Taichung
Karmanos Cancer Institute, Detroit
The University of Chicago Medical Center, Chicago
UCSF Helen Diller Family Comprehensive Cancer Center, Mission Bay, San Francisco
South Texas Accelerated Research Therapeutics, LLC, San Antonio
Ronald Reagan UCLA Medical Center, Los Angeles
Innovative Cancer Research Institute, Whittier
City of Hope Comprehensive Cancer Center, Duarte
Dana-Farber Cancer Institute, Boston
The University of Texas M.D. Anderson Cancer Center, Houston
Chonbuk National University Hospital, Jeonju
Seoul National University Bundang Hospital, Seongnam-si
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University, Seoul
Samsung Medical Center, Seoul
Gangnam Severance Hospital, Seoul
Korea University Anam Hospital, Seoul
Seoul St. Mary's Hospital, Seoul
SMG-SNU Boramae Medical Center, Seoul
Lead Sponsor
Five Prime Therapeutics, Inc.
INDUSTRY